

Helix BioMedix to Present on its Novel Antimicrobial Hexapeptides at Several Industry Conferences in May

Apr 18, 2006 - Bothell, Washington

Helix BioMedix, Inc. (HXBM.OB), a developer of bioactive peptides, today announced that members of its scientific staff will be presenting its novel antimicrobial hexapeptides at three industry conferences in May 2006. Dr. Timothy Falla, the company's Chief Scientific Officer, will present at TIDES® on May 1, 2006; Dr. Scott M. Harris, Director of Chemistry, will present at the Wound Healing Society 16th Annual Meeting and Exhibition on May 17, 2006; and Dr. Lijuan Zhang, Principal Scientist, will present at the 106th American Society for Microbiology Annual General Meeting on May 25, 2006.

"We are excited to have the opportunity to discuss recent advances related to our new class of hexapeptides at such important industry events," commented Dr. Falla. "In preclinical studies, these hexapeptides have activities previously thought to be restricted to peptides in excess of 15 residues in length. Not only are they more stable and active in biological environments, but they have many characteristics of therapeutic drugs and are capable of combating an increasing number of drug-resistant bacterial and fungal infections. They also appear to have low toxicity and are expected to be cost-effective to manufacture, key qualities required for commercial success. Dermatological applications we are working on include acne, dermatitis and rosacea."

Specific conference information is as follows:

TIDES® - Oligonucleotide and Peptide Technology and Product Development Conference 2006 titled "Proven Strategies for Successful Drug and Diagnostic Development" is being held May 1-4, 2006 at the La Costa Resort and Spa, Carlsbad, CA. Dr. Timothy Falla's presentation titled "Antimicrobial Hexapeptides: Structure, Activity and Cost" is scheduled for May 1, 2006 at 4:15PM PT (Track 2). TIDES® 2006 provides superior information and networking to scientists and executives involved in manufacturing therapeutics; raw materials, services and equipment for therapeutics; and diagnostics.

The Wound Healing Society 16th Annual Meeting & Exhibition is being held May 14-17, 2006 at the Double Tree Paradise Valley, Scottsdale, AZ. Dr. Scott M. Harris is presenting an abstract titled "Novel Hexapeptide Antimicrobials for the Prevention of Wound Infection" on May 17, 2006 at 3:00 pm local time during Concurrent Session #8 Wound Infection / Inflammation Response. Authors of the abstract include Dr. Scott M Harris, Dr. Lijuan Zhang, Dr. Jody Parente and Dr. Timothy J. Falla, all of Helix BioMedix, Inc. The Wound Healing Society, founded in 1990, is recognized among professionals and government agencies as the leading scientific organization focused on the area of wound healing.

The 106th American Society for Microbiology Annual General Meeting is being held May 21-25, 2006 at the Orange County Convention Center in Orlando, FL. Dr. Lijuan Zhang is presenting a poster of an Abstract titled "Novel Class of Hexapeptide Anti-Infective: A Structure Activity Profile" on May 25, 2006. Authors include Dr. Lijuan Zhang, Dr. Jody Parente, Dr. Scott M. Harris and Dr. Timothy Falla, all of Helix BioMedix, Inc. The American Society for Microbiology is the largest annual gathering of microbiologists in the world and showcases exciting advances and controversies in clinical microbiology and epidemiology,

pathogenesis and host defense, general and applied microbiology, microbial physiology, genetics and molecular biology, environmental microbiology, parasitology and virology.

About Helix BioMedix

Helix BioMedix, Inc. is a biopharmaceutical company that has a portfolio of issued patents that covers six distinct classes of peptides, including over 100,000 unique peptide sequences. The company's mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as topical anti-infectives and in wound healing applications. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More information about the company and its proprietary peptides can be found on the company's website at www.helixbiomedix.com.

Important Notice

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to our potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in our reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.